RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML

David G. J. Cucchi; Barbara Denys; Gertjan J.L. Kaspers; Jeroen J. W. M. Janssen; Gert J. Ossenkoppele; Válerie de Haas; C. Michel Zwaan; Marry M. van den Heuvel‐Eibrink; Jan Philippé; Tamás Csikós; Zinia J. Kwidama; Barbara De Moerloose; Eveline S.J.M. de Bont; Birgit I. Lissenberg‐Witte; Sonja Zweegman; Femke Verwer; Karl Vandepoele; Gerrit Jan Schuurhuis; Edwin Sonneveld; Jacqueline Cloos

doi:10.1182/blood-2017-12-819508

Abstract

Key Points FLT3-ITD-AR measurement based on RNA, but not DNA, is predictive for survival with a cutoff point of 0.5. FLT3-ITD-AR is associated with an ex vivo response to FLT3 inhibition with gilteritinib.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cucchi et al. (2018) studied this question.

synapsesocial.com/papers/6a1c00f7fc87fd06169cfb27 https://doi.org/10.1182/blood-2017-12-819508

View Full Paper

Ask AI

Bookmark

Share

RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML

Abstract

Discussion

Cite This Study

RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Blood

Keep reading

More related papers

More from Blood